Early Charm Announces Hiring of RC Dash as Applications Scientist for Rasio Therapeutics & SilcsBio

Updated: May 5

Dash to bring pharmacology background to drive product development

for Rasio Therapeutics and design services for SilcsBio


April 27, 2022, Baltimore, MD – Early Charm, a company that creates, owns and operates ventures that convert science to revenue, today announced the hiring of RC Dash, an accomplished pharmacologist with significant research experience in drug design, as Applications Scientist.


In his new role, Dash will work with Early Charm’s Drug Design portfolio companies, Rasio Therapeutics and SilcsBio, to provide expertise in rational hit identification, hit-to-lead optimization, molecular modeling and compound screening.

Dash earned his PhD at Poona College of Pharmacy, Pune, India, concentrating on the design, synthesis and pharmacological evaluation of new chemical entities as potential atypical antipsychotic agents.


In his most recent position, Dash worked as a postdoctoral researcher at the University of Connecticut, focusing on the identification of new ligands as TLS and Hh signaling inhibitors. He also worked on understanding the molecular recognition of complex biological systems at the atomic level using computational methods.


As part of his academic and research background, Dash’s experience also includes computational study including rational drug design, small molecule synthesis and evaluation.


“When SilcsBio partnered to create the Rasio joint venture, we knew we needed someone with strong medicinal chemistry knowledge,” said Ken Malone, Executive Officer with Early Charm. “RC brings that area of expertise and gives us a way to accelerate further our product development and customer service efforts.”


About Rasio Therapeutics:

Rasio is a Maryland-based biopharmaceutical company that develops novel medicines using a cutting edge-computer-aided drug design technology. Rasio has partnered with SilcsBio, LLC, a leader in computational drug discovery, to develop small molecules for exciting but previously inaccessible disease targets. Rasio is initially focusing on oncology and has raised seed funding to design and develop several oncology therapeutics for areas of significant unmet medical need. Learn more: www.rasiotx.com


About SilcsBio:

SilcsBio, LLC offers the SILCS platform technology that advances computational drug design applications through detailed protein mapping that accounts for flexibility and solvation and enables highly efficient ligand binding evaluation, virtual screening, and more. SilcsBio software and services span from target protein mapping and analysis through lead optimization and offers key insights for biological therapeutic formulations. The proprietary software unlocks hidden binding hotspots of target proteins and reveals the preferred ligand chemistries at those sites to rapidly guide the drug design process. SilcsBio most recently announced a partnership with Aikido Pharmaceuticals. Learn more: www.silcsbio.com


About Early Charm:

Early Charm creates, owns and operates businesses that convert science into revenue. We are the management team, the operators and the entrepreneurs. We don’t write checks and just pop in for board meetings. We show up to our labs, our production facilities and our offices every day to do all the heavy lifting in our portfolio companies. Learn more: www.earlycharm.com


Media Contact:

Ken Berlack

Early Charm

ken.berlack@earlycharm.com

79 views